Live Micron Technology Inc Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about

Most recent public disclosures: AI-powered summaries of the latest corporate filings

31801
1
SERA PROGNOSTICS, INC. Sera Prognostics Reports Decline in Revenue and Net Loss in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

31802
1
TANDEM DIABETES CARE INC Tandem Diabetes Care Reports 31% Revenue Growth, Narrowing Losses in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

31803
1
Blue Owl Capital Corp Blue Owl Capital Reports 8% Increase in Total Investments, Net Asset Value Decline in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

31804
1
IRON MOUNTAIN INC Iron Mountain Reports 12.2% Revenue Growth, Net Loss in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

31805
1
Contineum Therapeutics, Inc. Contineum Therapeutics Reports Improved Financial Position, Net Losses Amid Clinical Development Expenses

Via official filing (AI summary) | over 1 year ago | 0 comments

31806
1
IonQ, Inc. IonQ Reports 102% Revenue Growth, Net Loss Widens in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

31807
1
Voya Financial, Inc. Voya Financial Reports 7.3% Revenue Growth, Net Income Decline in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

31808
1
Seneca Foods Corp Seneca Foods Reports Mixed Quarter, Revenue Growth Offset by Decreased Profitability

Via official filing (AI summary) | over 1 year ago | 0 comments

31809
1
Revolution Medicines, Inc. Revolution Medicines Reports Significant Revenue Decline, Increased Expenses, and Net Loss in Latest Quarter

Via official filing (AI summary) | over 1 year ago | 0 comments

31810
1
Nextdoor Holdings, Inc. Nextdoor Reports 17% Revenue Growth, Net Loss Improvement in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

31811
1
Personalis, Inc. Personalis Reports 41% Revenue Growth, Net Loss in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

31812
1
Allakos Inc. Allakos Inc. Reports Significant Financial Decline, Net Loss in Latest Quarter

Via official filing (AI summary) | over 1 year ago | 0 comments

31813
1
INNOVATE Corp. INNOVATE Corp. Reports Revenue Decline, Net Losses, and Strategic Initiatives in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

31814
1
Grocery Outlet Holding Corp. Grocery Outlet Reports 9.9% Revenue Growth, Net Income Decline in 39-Week Period Ended September 28, 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

31815
1
Xencor Inc Xencor Reports Significant Revenue Decline and Increased Losses in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

31816
1
Whitehawk Therapeutics, Inc. Aadi Bioscience Reports Q3 2024 Financial Results, Product Sales Growth, and Reduced Net Loss

Via official filing (AI summary) | over 1 year ago | 0 comments

31817
1
Caribou Biosciences, Inc. Caribou Biosciences Reports Significant Financial Decline, Net Loss Widens in Latest Quarter

Via official filing (AI summary) | over 1 year ago | 0 comments

31818
1
CATALYST PHARMACEUTICALS, INC. Catalyst Pharmaceuticals Reports Significant Revenue Growth and Improved Financials in Latest Quarter

Via official filing (AI summary) | over 1 year ago | 0 comments

31819
1
PROFIRE ENERGY INC Profire Energy Reports Modest Revenue Growth, Decline in Profitability in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

31820
1
Grand Canyon Education, Inc. Grand Canyon Education Reports 7.4% Revenue Growth, 16.0% Net Income Increase in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

31821
1
Arcutis Biotherapeutics, Inc. Arcutis Biotherapeutics Reports 17% Revenue Growth, 452% Increase in Product Revenue in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

31822
1
IONIS PHARMACEUTICALS INC Ionis Pharmaceuticals Reports Mixed Q3 Results, Net Loss Improves

Via official filing (AI summary) | over 1 year ago | 0 comments

31823
1
TEVA PHARMACEUTICAL INDUSTRIES LTD Teva Pharmaceutical Reports 13% Revenue Growth, Net Loss in Q3 2024 Due to Increased Legal Settlements and Goodwill Impairment

Via official filing (AI summary) | over 1 year ago | 0 comments

31824
1
SOLENO THERAPEUTICS INC Soleno Therapeutics Reports Significant Financial Changes, Net Losses Increase 673% in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments

31825
1
Blue Owl Capital Corp III Blue Owl Capital Corporation III Reports Mixed Financial Results in Latest 10-Q Filing

Via official filing (AI summary) | over 1 year ago | 0 comments